Target intelligence / Profile preview

Aldehyde dehydrogenase 6 family member A1 (ALDH6A1)

Target
ALDH6A1
Molecular classification
Enzyme, Mitochondrial protein, Aldehyde dehydrogenase family
01

Overview

Aldehyde dehydrogenase 6 family member A1 (ALDH6A1) is a mitochondrial enzyme belonging to the aldehyde dehydrogenase family. It catalyzes the irreversible oxidative decarboxylation of malonate and methylmalonate semialdehydes to form acetyl-CoA and propionyl-CoA, essential steps in the catabolism of valine and pyrimidine. Mutations in the ALDH6A1 gene cause a rare metabolic disorder—methylmalonate semialdehyde dehydrogenase deficiency—characterized by accumulation of organic acids in urine and variable neurodevelopmental consequences. Reduced expression of ALDH6A1 is linked to enhanced proliferation in certain cancers, indicating its role in tumorigenesis and its potential as a prognostic biomarker. The enzyme is most highly expressed in the kidney and liver, localized to mitochondria, and contributes to energy and intermediary metabolic regulation.

Other names
Methylmalonate-semialdehyde dehydrogenase [acylating], mitochondrialMMSDHMalonate-semialdehyde dehydrogenase (acetylating)Mitochondrial acylating methylmalonate-semialdehyde dehydrogenaseMMSADHATesticular tissue protein Li 122
02

Mechanism of action

Enzymatic oxidation (targeted drugs would act by modulating its activity, but there is no evidence of current clinical drugs directly targeting this enzyme)

03

Biological functions

Catalysis of the irreversible oxidative decarboxylation of malonate and methylmalonate semialdehydes to acetyl- and propionyl-CoAKey role in valine and pyrimidine catabolic pathwaysEsterase activity characteristic of aldehyde dehydrogenase enzymesRegulation of intermediary metabolism and energy homeostasis
04

Disease associations

Metabolic disorder (methylmalonate semialdehyde dehydrogenase deficiency, with symptoms that can include global developmental delay and lactic acidosis)Cancer (downregulation associated with some tumors, such as clear cell renal cell carcinoma)
05

Safety considerations

No direct safety concerns reported for modulating this target. However, its disruption can cause metabolic disorders, which suggests risks in inhibition or loss of function.
06

Biomarkers

Urinary levels of 3-hydroxyisobutyric acidBeta-alanine3-hydroxypropionic acidALDH6A1 protein expression levels (potential biomarker in prostate and kidney cancers)

Beyond the preview

Go deeper on Aldehyde dehydrogenase 6 family member A1 (ALDH6A1).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Aldehyde dehydrogenase 6 family member A1 (ALDH6A1).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call